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Abstract: 
Background: Wound healing disturbance is a common complication 
following surgery, but the underlying cause sometimes remains elusive.  
Case presentation: A 50 years old Caucasian male developed an initially 
misunderstood severe wound healing disturbance following colon and 
abdominal wall surgery. An untreated alpha-1-antitrypsin deficiency in the 
patient’s medical history, known since 20 years and clinically apparent as a 
mild to moderate chronic obstructive pulmonary disease, was eventually 
found to be at its origin. Further clinical work-up showed alpha-1-
antitrypsin serum levels below 30% of the lower reference value, 
phenotype testing revealed a ZZ phenotype and a biopsy taken from the 
wound area showed the characteristic, disease-related histological pattern 
of necrotising panniculitits. Augmentation therapy with plasma alpha-1-
antitrypsin was initiated and within a few weeks, rapid and adequate would 
healing was observed.  
Conclusion: Alpha-1-antitrypsin deficiency is an uncommon but clinically 
significant, possible cause of wound healing disturbances. An augmentation 
therapy ought to be considered in affected patients during the 
perioperative period.    
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Background 
Wound healing disturbance is a frequent postoperative complication, generally caused by a 
combination of surgery-related factors and patient’s condition including duration of the intervention, 
contamination of the operative field or wound site, age, nutritional status and other risk factors such as 
regular intake of steroids or immunosuppressants as well as smoking and cardiovascular disease 
entailing tissue hypoxia. At the other end of the spectrum, Alpha-1-antitrypsin (AAT) deficiency has 
been described as a rare cause of impaired wound healing
1
.  
AAT deficiency is the most commonly inherited metabolic disease, mainly predisposing to liver and 
lung injury. AAT is an abundantly circulating serine protease inhibitor that basically neutralizes 
neutrophil elastase2. In case of reduction or absence of AAT the inhibition of elastase and subsequent 
prevention of tissue destruction is diminished. According to the mobility of the protein inhibitor  in the 
electrophoresis, four different phenotypes can be differentiated referred to as M (medium), S (slow), Z 
(very slow) and null phenotype
3
. The MM phenotype represents the wildtype, whereas the ZZ is 
associated with the severest clinical progression4,5. The ZZ variant results in normal synthesis of AAT, 
but only 15% of the produced enzyme are secreted from the hepatocytes6. Clinical symptoms can be 
observed when the serum concentration of AAT is below 35% of the average standard level7. 
According to the phenotype, the prevalence of this autosomal recessive disorder varies between 0.015 
and 0.04%, accounting for an estimated number of up to 296’000 affected patients in the entire 
Europe4,8-10. The most common clinical manifestations of AAT deficiency are panacinar pulmonary 
emphysema and liver cirrhosis11,12. However, AAT deficiency associated necrotising panniculitis has 
been described in the literature as a rare, but specific cause of delayed wound healing13,14. 
We present a case of a patient suffering from a severe postoperative wound healing disturbance due to 
an AAT deficiency associated panniculitis. The pertinent literature will be reviewed and discussed. 
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Case report 
A 53 year old Caucasian male patient was urgently hospitalised at Bern University Hospital and a 
steroid treatment (Methylprednisolon 125 mg/d) for an assumed systemic capillary leak syndrome 
(Clarkson’s disease) was initiated. Patient’s history revealed a poor nutritional status and a chronic 
obstructive pulmonary disease (Gold II, FEV1 = 57% of the standard). The latter possibly being 
attributed to the AAT deficiency diagnosed 20 years ago, yet untreated since then. After three days of 
therapy, the patient developed an acute abdomen requiring emergency laparotomy. A perforation of 
the caecum with fecal peritonitis was encountered, and an ileo-caecal resection with an abdominal split 
(ileum/ascending colon) ostomy were performed via an open laparotomy. 
Owing to an ankylosing spondylitis, the patient was receiving regular (every eight weeks) infusions of 
the immunosuppressant infliximab, the last dose dating back 48 hours before admission. At time of 
first surgery, a spontaneous blister of unknown origin was located at the right side of the abdomen. 
After its debridement, an open, fibrin-coated wound remained.   
Eight days after primary surgery the patient developed a complete dehiscence of the laparotomy. 
Abdominal wall closure was achieved using an intra-peritoneal onlay mesh (IPOM), and a vacuum-
assisted device (VAC) was installed at a continuous negative pressure of 25mmHg in order to enhance 
wound healing. The VAC was subsequently changed three times a week. However, neither the 
laparotomy wound nor the debrided blister in the flank showed any sign of granulation tissue (Figure 
1a and b, 1f and g). Even worse, further skin lesions developed, one in the right lower abdomen 
beneath the ostomy, another upon the sacrum, both reminding the clinical aspects of the blister and the 
laparotomy wounds. The wounds in the right flank and upon the sacrum were each dressed using a 
VAC device.  
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Given the utter absence of wound healing for more than ten weeks, extended diagnostic evaluation for 
connective tissue disease, vasculitis and anti-phospholipid syndrome as well as serologic testing for 
various viral infections including human immuno-deficiency virus (HIV) and hepatitis were 
performed. None of these analyses yielded further clues about the aetiology of the pending wound 
healing disorder. A biopsy taken from the blister wound in the right flank revealed a necrotising 
panniculitis.  
AAT serum concentration was found to be significantly decreased to 0.25g/L (standard values: 0.90 to 
2.00g/L), and genetic testing showed a ZZ phenotype. Based on these findings, augmentation therapy 
using AAT (Prolastin®, Crucell, Bern, Switzerland, 60mg per kilogram weekly) was started. Within 7 
days after initiation of the treatment, significant granulation tissue and wound healing could be 
observed (Figure 1c). After eight weeks of periodic ATT infusions, serum concentration was within 
standard values at 0.92g/L, and all VAC devices could eventually be removed definitely (Figure 1 d 
and e). Another ten weeks later the skin lesions were all completely cured and the patient was 
discharged to a rehabilitation centre.  
 
Conclusion 
AAT deficiency is typically characterised by pulmonal emphysema and liver cirrhosis
15
. Necrotising 
panniculitis was shown to be a possible complication of AAT deficiency. AAT associated panniculitis 
typically presents with recurrent painful, red nodules or plaques, suppurated ulcerations and 
expression of oily discharge from the skin lesions refractory to usual treatment, namely to steroids7,16. 
Occurrence of the inflammation is often related to antecedent trauma or excessive activity, and 
predilection sites are thighs, buttock and trunk
3
. Histology is characterised through abundant 
neutrophil granulocytes and lobular fat necrosis 
17
. Histological overhaul of the wound biopsy from the 
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blister’s ground in the right flank showed the typical signs of necrotising panniculitis. In the present 
case, two skin lesions can be ascribed to traumatic conditions, the laparotomy to the surgical 
intervention and the sacral wound to the bedriddenness. The blister in the right flank, however, could 
not be attributed to a specific traumatic event.   
Differential diagnosis includes wound healing disturbance due to high-dose steroid or infliximab 
therapy and malnutrition, respectively. However, steroid therapy was discontinued after three days of 
application and the wound repair failure persisted more than 10 weeks after weaning of the steroid 
therapy. Infliximab is reported to lose its effect within 4 to 8 weeks after administration
18
. This casts 
steroids and infliximab as a possible causes for the wound healing disturbance into doubt. 
Furthermore, short-term application (<10 days) of even high doses of steroids do not seem be a risk 
factor for impaired wound healing19. Initial nutrient deficiency was substituted by parenteral nutrition 
and enteral feeding via a naso-jejunal tube (at admission: Albumin 23g/L; reference values: 35 – 
52g/L). Serum albumin were found to be within standard levels 39 days after the initial operation. 
The ZZ phenotype determined by the genetic studies in this patient is generally associated with the 
severest clinical manifestation of AAT deficiency, including lung and liver disease as well as 
panniculitis and wound healing disturbances20. While a liver affection was never diagnosed in our 
patient, he is suffering from several diseases that could be associated with AAT deficiency, including 
chronic obstructive pulmonary disease (Gold stadium II), hypothyroidism, ankolysing spondylitis, and  
panniculitis 13. However, the pathogenesis of panniculitis in the context of AAT deficiency remains 
unknown and there is no correlation described between serologic AAT values and the occurrence of 
panniculitis. In the literature even some patients with phenotype MS, who have normal AAT serum 
levels, were reported to develop panniculits
16
.  
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In the presented case, intravenous substitution of human purified enzyme (Prolastin®) entailed 
formation of granulation tissue at one week, and normalisation of serum levels of AAT,at three weeks 
after starting the therapy, respectively. The persistent wound healing failure whilst AAT deficiency 
was untreated and prompt formation of granulation tissue after onset of the augmentation therapy 
suggests respective causality. Appropriate histology as well as serum concentration of AAT of below 
30% of the lower reference value prior to treatment further support the diagnosis of AAT deficiency 
related wound healing impairment. Successful augmentation therapy of AAT deficiency associated 
panniculits has been described earlier
21
. While other cases reported in the literature were treated with 
either tetracycline, steroids, non-steroidal anti-inflammatory drugs or hydroxychloroquine, 
individualized Prolastin® therapy in terms of starting time of application and dosage  showed to be the 
most effective treatment strategy22. To date, no adverse effects of AAT substitution are documented, 
but no long-term data are available
23
. 
In summary, AAT deficiency should be considered as a possible cause of wound healing impairment, 
particularly if lack of the enzyme is already recorded in patient’s medical history. Furthermore, when 
intractable perioperative wound healing disturbance of unknown origin persists AAT deficiency 
should be considered as differential diagnosis. This case report represents, to our knowledge, the first 
published case of AAT deficiency related wound healing problems after surgery. Diagnosis is made 
based on AAT serum levels, genetic test and the occurrence of histologically proven panniculitis. The 
pathogenesis of fat tissue inflammation in the context of AAT deficiency has not yet been elucidated. 
Yet, intravenous Prolastin® substitution seems to be the most effective treatment strategy. We 
therefore suggest to assess AAT serum levels in patients with a known deficiency prior to surgical 
intervention. If criteria of AAT deficiency are met, preventive substitution therapy should be 
considered to avoid postoperative wound healing failure. 
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Figure 1: Laparostomy and wound area of the blister after debridement. No granulation tissue has 
occurred until initiating augmentation therapy. Pictures show the chronology of the wound healing, 
including number of days after the first surgery (1. digit) and the time before and after the beginning 
of the substitution (2. digit, in days). a) +32/ -41, b) +55/ -18, c) +86/ +13, d) +107/ +34, e) +142/ +69, 
f) +28/ -45, g) +55/ -18, h) +79/ +6, i) +107/ +34, k) +142/ +69.  
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Key Points 
Wound healing disturbance is a common complication following surgery. Sometimes the underlying 
reason remains elusive and no accurate therapy can be induced. In this report, a case of necrotising 
panniculitis due to an untreated alpha-1-antitrypsin deficiency is described. Within a few weeks after 
initiation of the augmentation therapy with plasma alpha-1-antitrypsin, an adequate wound healing 
was observed. This case should show a further cause for a wound healing disturbance, which can be 
easily treated.  
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Background 
Wound healing disturbance is a frequent postoperative complication, generally caused by a 
combination of surgery-related factors and patient’s condition. These include duration of the 
intervention, contamination of the operative field or wound site, age, nutritional status and other risk 
factors such as regular intake of steroids or immunosuppressants as well as smoking and 
cardiovascular disease entailing tissue hypoxia. At the other end of the spectrum, Alpha-1-antitrypsin 
(AAT) deficiency has been described as a rare cause of impaired wound healing
1
.  
AAT deficiency is the most commonly inherited metabolic disease, characteristically predisposing to 
liver and lung injury. AAT is an abundantly circulating serine protease inhibitor that neutralizes 
neutrophil elastase2. In case of reduction or absence of AAT the inhibition of elastase and subsequent 
prevention of tissue destruction is diminished. According to the mobility of the protein inhibitor  in the 
electrophoresis, four different phenotypes can be differentiated referred to as M (medium), S (slow), Z 
(very slow) and null phenotype
3
. The MM phenotype represents the wildtype, whereas the ZZ is 
associated with the severest clinical progression4,5. The ZZ variant results in normal synthesis of AAT, 
but only 15% of the produced enzyme are secreted from the hepatocytes6. Clinical symptoms can be 
observed when the serum concentration of AAT is below 35% of the average standard level7. 
According to the phenotype, the prevalence of this autosomal recessive disorder varies between 0.015 
and 0.04%, accounting for an estimated number of up to 296’000 affected patients in Europe
4,8-10
. The 
most common clinical manifestations of AAT deficiency are panacinar pulmonary emphysema and 
liver cirrhosis11,12. In addition, AAT deficiency associated necrotising panniculitis has been described 
in the literature as a rare, but specific cause of delayed wound healing13,14. 
We present a case of a patient suffering from a severe postoperative wound healing disturbance due to 
an AAT deficiency associated panniculitis. The literature will be reviewed and discussed. 
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Case report 
A 53 year old Caucasian male patient was hospitalised at Bern University Hospital for acute renal 
failure, and steroid treatment (Methylprednisolon 125 mg/d) for an assumed systemic capillary leak 
syndrome (Clarkson’s disease) was initiated. Patient’s history revealed a poor nutritional status and a 
chronic obstructive pulmonary disease (Gold II, FEV1 = 57% of the standard), the latter possibly being 
attributed to an AAT deficiency diagnosed 20 years ago, yet untreated since then. After three days of 
therapy, the patient developed an acute abdomen requiring emergency laparotomy. A perforation of 
the caecum with fecal peritonitis was encountered, and an ileo-caecal resection with an abdominal split 
(ileum/ascending colon) ostomy were performed via an open laparotomy. 
Owing to an ankylosing spondylitis, the patient was receiving regular (every eight weeks) infusions of 
the immunosuppressant infliximab, the last dose dating back 48 hours before admission. At time of 
first surgery, a spontaneous blister of unknown origin developed at the right side of the abdomen. 
After its debridement, an open, fibrin-coated wound remained.   
Eight days after primary surgery, the patient developed a burst abdomen. Abdominal wall closure was 
achieved using an intra-peritoneal onlay mesh (IPOM), and a vacuum-assisted device (VAC) was 
installed at a continuous negative pressure of 25mmHg in order to enhance wound healing. The VAC 
was subsequently changed three times a week. However, neither the laparotomy wound nor the 
debrided blister in the flank showed any sign of granulation tissue (Figure 1a and b, 1f and g). Even 
worse, further skin lesions developed, one in the right lower abdomen beneath the ostomy, another 
upon the sacrum, both reminding the clinical aspects of the blister and the laparotomy wounds. The 
wounds in the right flank and upon the sacrum were each treated using a VAC device.  
Given the utter absence of wound healing for more than ten weeks, extended diagnostic evaluation for 
connective tissue disease, vasculitis and anti-phospholipid syndrome as well as serologic testing for 
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various viral infections including human immuno-deficiency virus (HIV) and hepatitis were 
performed. None of these analyses yielded further clues about the aetiology of the lack of wound 
healing disorder. A biopsy taken from the blister wound in the right flank revealed a necrotising 
panniculitis.  
Finally, AAT serum concentration was tested and found to be significantly decreased to 0.25g/L 
(standard values: 0.90 to 2.00g/L), and genetic testing confirmed a ZZ phenotype. Based on these 
findings, augmentation therapy using AAT (Prolastin®, Crucell, Bern, Switzerland, 60mg per 
kilogram weekly) was started. Within 7 days after initiation of the treatment, significant granulation 
tissue developed and wound healing could be observed (Figure 1c). After eight weeks of periodic ATT 
infusions, serum concentration was within standard values at 0.92g/L, and all VAC devices could be 
removed definitely (Figure 1 d and e). Another ten weeks later, the skin lesions were all completely 
cured, and the patient was discharged to a rehabilitation centre.  
 
Conclusion 
AAT deficiency is typically characterised by pulmonal emphysema and liver cirrhosis15. Necrotising 
panniculitis was shown to be a possible complication of AAT deficiency. AAT associated panniculitis 
typically presents with recurrent painful, red nodules or plaques, suppurated ulcerations and 
expression of oily discharge from the skin lesions refractory to usual treatment, namely to steroids
7,16
. 
Development of lesions is often related to antecedent trauma or excessive activity, and predilection 
sites are thighs, buttock and trunk3. Histology is characterised through abundant neutrophil 
granulocytes and lobular fat necrosis 17. The histology of the wound biopsy from the blister’s ground 
in the right flank showed the typical signs of necrotising panniculitis. In the present case, two skin 
lesions can be ascribed to traumatic conditions, the laparotomy to the surgical intervention and the 
Page 13 of 18 International Wound Journal
For Review
 O
nly
  Cathomas et al.   p.4 
sacral wound to the bedriddenness. The blister in the right flank, however, could not be attributed to a 
specific traumatic event. 
Differential diagnosis includes wound healing disturbance due to high-dose steroid or infliximab 
therapy and malnutrition, respectively. Steroid therapy was applied for only three days, and the most 
recent dose of infliximab was administered 48 hours before the initial hospitalization. Furthermore, 
short-term application (<10 days) of even high doses of steroids do not seem to be a risk factor for 
impaired wound healing
19
, and infliximab is reported to lose its effect within 4 to 8 weeks after 
administration
18
. The wound repair failure, however, persisted more than 10 weeks after weaning of 
the steroid and infliximab therapy, making the two drugs unlikely to be the cause of the persistent  
wound healing disturbance. Initial nutrient deficiency was substituted by parenteral nutrition and 
enteral feeding via a naso-jejunal tube (at admission: Albumin 23g/L; reference values: 35 – 52g/L). 
Serum albumin was found to be within standard l vels 6 weeks after the initial operation. 
The ZZ phenotype determined by the genetic studies in this patient is generally associated with the 
severest clinical manifestation of AAT deficiency, including lung and liver disease as well as 
panniculitis and wound healing disturbances20. While a liver affection was never diagnosed in our 
patient, he is suffering from several diseases that could be associated with AAT deficiency, including 
chronic obstructive pulmonary disease (Gold stadium II), hypothyroidism, ankolysing spondylitis, and  
panniculitis 
13
. However, the pathogenesis of panniculitis in the context of AAT deficiency remains 
unknown and there is no correlation described between serologic AAT values and the occurrence of 
panniculitis. In the literature even some patients with phenotype MS, who have normal AAT serum 
levels, were reported to develop panniculits16.  
In the presented case, intravenous substitution of human purified enzyme (Prolastin®) leads to the 
formation of granulation tissue after one week and normalisation of serum levels of AAT three weeks 
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after starting therapy, respectively. The persistent wound healing failure whilst AAT deficiency was 
untreated and prompt formation of granulation tissue after onset of the augmentation therapy suggests 
respective causality. Appropriate histology as well as serum concentration of AAT of below 30% of 
the lower reference value prior to treatment further supports the diagnosis of AAT deficiency related 
wound healing impairment. Successful augmentation therapy in spontaneous occurring AAT 
deficiency associated panniculits lesions has been described
21
. While other cases reported in the 
literature were treated with either tetracycline, steroids, non-steroidal anti-inflammatory drugs or 
hydroxychloroquine, individualized Prolastin® therapy in terms of starting time of application and 
dosage  showed to be the most effective treatment strategy22. To date, no adverse effects of AAT 
substitution are documented, but no long-term data are available23. 
In summary, AAT deficiency should be considered as a possible cause of wound healing impairment, 
particularly if lack of the enzyme is already recorded in patient’s medical history. Furthermore, when 
intractable perioperative wound healing disturbance of unknown origin persists, AAT deficiency 
should be considered in the differential diagnosis. This case report represents, to our knowledge, the 
first published case of AAT deficiency related wound healing problems after surgery. Diagnosis is 
made based on AAT serum levels, genetic test and the occurrence of histologically proven 
panniculitis. The pathogenesis of fat tissue inflammation in the context of AAT deficiency has not yet 
been elucidated. Yet, intravenous Prolastin® substitution seems to be the most effective treatment 
strategy. We therefore suggest to assess AAT serum levels in patients with a known deficiency prior to 
surgical intervention. If criteria of AAT deficiency are met, preventive substitution therapy should be 
considered to avoid postoperative wound healing failure. 
Figure 1: Laparostomy and wound area of the blister after debridement. No granulation tissue has 
occurred until initiating augmentation therapy. Pictures show the chronology of the wound healing, 
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including number of days after the first surgery (1. digit) and the time before and after the beginning 
of the substitution (2. digit, in days). a) +32/ -41, b) +55/ -18, c) +86/ +13, d) +107/ +34, e) +142/ +69, 
f) +28/ -45, g) +55/ -18, h) +79/ +6, i) +107/ +34, k) +142/ +69.  
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